← All trials
NCT03548766
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2018
- Primary completion
- Oct 31, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hamad Medical CorporationLead sponsor
- Hamad Medical CorporationReponsible party - principal investigator
- Hamad Medical CorporationOverall official - principal investigator
- Anti-Doping Lab QatarStudy chair
- Anti-Doping Lab QatarOverall official - principal investigator
- Anti-Doping Lab QatarCollaborator
- Laboratorio Antidoping FMSICollaborator
- Laboratorio Antidoping FMSIOverall official - principal investigator
- Sidra Medical and Research CenterCollaborator
- Sidra Medical and Research CenterOverall official - principal investigator
- World Anti-doping AgencyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.